The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide and salbutamol sulfate (albuterol sulfate) used in the management of chronic obstructive pulmonary disease (COPD) and asthma (not an FDA approved usage). It is marketed by Boehringer Ingelheim as metered dose inhaler (MDI) and nebuliser preparations under the trade name Combivent. Besides, it is marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb as a nebulizer. In Italy it is known as Breva.sold in India by cipla as duolin
Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries.
Read more about Ipratropium Bromide/salbutamol: DuoNeb Controversy